Review Actual status of therapeutic vaccination in non-small cell lung cancer

Szyszka-Barth, Katarzyna; Ramlau, Katarzyna; Goździk-Spychalska, Joanna; Spychalski, L; Bryl, Maciej; Gołda-Gocka, Iwona; Kopczyńska, Anna; Barinow‐Wojewódzki, Aleksander

doi:10.5114/wo.2014.42724

Cited by 6 publications

(3 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cancer cytotherapy is a novel therapeutic approach with great potential [ 22 – 24 ]. Since the report of the first DCs-based cancer vaccine clinical trial in 1995 [ 25 ], a lot of trials have been designed and conducted [ 26 , 27 ].…”

Section: Discussionmentioning

confidence: 99%

Feasibility study of DCs/CIKs combined with thoracic radiotherapy for patients with locally advanced or metastatic non-small-cell lung cancer

Zhang

Shen

et al. 2016

Radiat Oncol

View full text Add to dashboard Cite

BackgroundThe combination of dendritic cells (DCs) and cytokine-induced killer cells (CIKs) can induce the anti-tumor immune response and radiotherapy may promote the activity. We aimed to explore the feasibility of DCs/CIKs combined with thoracic radiotherapy (TRT) for patients with locally advanced or metastatic non-small-cell lung cancer (NSCLC).MethodIn this study, patients with unresectable stage III/IV NSCLC and an Eastern Cooperative Oncology Group performance status (ECOG PS) of 0–2 and previously receiving two or more cycles of platinum-based doublet chemotherapy without disease progression received TRT plus DCs/CIKs or TRT alone until disease progression or unacceptable toxicity. The primary endpoint was median progression-free survival (mPFS). In treatment group, patients received four-cycle autologous DCs/CIKs infusion starting from the 6th fraction of irradiation.ResultsFrom Jan 13, 2012 to June 30, 2014, 82 patients were enrolled, with 21 patients in treatment group and 61 in control group. The mPFS in treatment group was longer than that in control group (330 days vs 233 days, hazard ratio 0.51, 95 % CI 0.27–1.0, P < 0.05), and the objective response rate (ORR) of treatment group (47.6 %) was significantly higher that of control group (24.6 %, P < 0.05). There was no significant difference in disease control rate (DCR) and median overall survival (mOS) between two groups (P > 0.05). The side effects in treatment group were mild and there was no treatment-related deaths.ConclusionThe combination of DCs/CIKs with TRT could be a feasible regimen in treating locally advanced or metastatic NSCLC patients. Further investigation of the regimen is warranted.

show abstract

Section: Discussionmentioning

confidence: 99%

Feasibility study of DCs/CIKs combined with thoracic radiotherapy for patients with locally advanced or metastatic non-small-cell lung cancer

Zhang

Shen

et al. 2016

Radiat Oncol

View full text Add to dashboard Cite

show abstract

“…These studies have shown that a subset of patients benefit from vaccination, with clinical benefit being confined to those who respond most robustly in immunologic terms. The overarching lesson from these trials is that responses to therapeutic vaccines can be significant, but are generally limited to a subset of patients . We hypothesized that using a vaccine as a preventive strategy could enable the polarization of an immune response capable of successfully eliminating early lesions and preventing tumor development in the lung.…”

Section: Introductionmentioning

confidence: 99%

Epidermal growth factor receptor derived peptide vaccination to prevent lung adenocarcinoma formation: An in vivo study in a murine model of EGFR mutant lung cancer

Ebben

Lubet

Gad

et al. 2015

Molecular Carcinogenesis

View full text Add to dashboard Cite

The ability to prevent disease is the holy grail of medicine. For decades, efforts have been made to extend the successes seen with vaccination against infectious diseases to cancer. In some instances, preventive vaccination against viruses (prototypically HPV) has successfully prevented tumorigenesis and will make a major impact on public health in the decades to come. However, the majority of cancers that arise are a result of genetic mutation within the host, or non-viral environmental exposures. We present compelling evidence that vaccination against an overexpressed self-tumor oncoprotein has the potential to prevent tumor development. Vaccination against the Epidermal Growth Factor Receptor (EGFR) using a multipeptide vaccine in a preventive setting decreased EGFR-driven lung carcinogenesis by 76.4% in a mouse model of EGFR-driven lung cancer. We also demonstrate that anti-EGFR vaccination primes the development of a robust immune response in vivo. This study provides proof of concept for the first time that targeting tumor drivers in a preventive setting in lung cancer using peptide vaccination can inhibit tumorigenesis and may provide useful clinical insights into the development of strategies to vaccinate against EGFR in populations that where EGFR-mutant disease is highly prevalent.

show abstract

“…Lung cancer is becoming the leading cause of cancer-associated mortality worldwide, particularly in China ( 1 , 2 ). For patients with lung cancer, resistance to therapy is a common phenomenon, which threatens the success of the treatment currently used against the disease.…”

Section: Introductionmentioning

confidence: 99%

Luteolin exerts an anticancer effect on NCI-H460 human non-small cell lung cancer cells through the induction of Sirt1-mediated apoptosis

Peng

et al. 2015

Molecular Medicine Reports

View full text Add to dashboard Cite

Luteolin is a falconoid compound, which exhibits anticancer properties, however, its contribution to Sirt1-mediated apoptosis in human non-small cell lung cancer remains to be elucidated. The present study confirmed that the anticancer effect of luteolin on NCI-H460 cells was through Sirt1-mediated apoptosis. The NCI-H460 cells were treated with different concentrations of luteolin, and a 3-(4,5-dimeth yl-2-thiazolyl)-2,5-diphnyl-2H-tetrazolium bromide assay, cell cycle analysis and annexin-V/fluorescein isothiocyanate and propidium double staining were performed to assess the apoptotic effect of luteolin. Wound healing and Transwell assays were performed to confirm the inhibition of NCI-H460 cell migration. The protein levels of Sirt1 were knocked down in the NCI-H460 cells using a lentivirus to further investigate the role of this protein, and the expression levels of the apoptotic associated proteins, Bad, Bcl-2, Bax, caspase-3 and Sirt1, were measured using western blotting. The results of the present study demonstrated that luteolin exerted an anticancer effect against NCI-H460 cells through Sirt1-mediated apoptosis and the inhibition of cell migration.

show abstract

Review Actual status of therapeutic vaccination in non-small cell lung cancer

Cited by 6 publications

References 56 publications

Feasibility study of DCs/CIKs combined with thoracic radiotherapy for patients with locally advanced or metastatic non-small-cell lung cancer

Feasibility study of DCs/CIKs combined with thoracic radiotherapy for patients with locally advanced or metastatic non-small-cell lung cancer

Epidermal growth factor receptor derived peptide vaccination to prevent lung adenocarcinoma formation: An in vivo study in a murine model of EGFR mutant lung cancer

Luteolin exerts an anticancer effect on NCI-H460 human non-small cell lung cancer cells through the induction of Sirt1-mediated apoptosis

Contact Info

Product

Resources

About